Cargando…
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer
Gemcitabine (GEM) resistance is a critical issue for pancreatic cancer treatment. The involvement of epigenetic modification in GEM resistance is still unclear. We established a GEM-resistant subline PANC-1-R from the parental PANC-1 pancreatic cancer cells and found the elevation of various chromat...
Autores principales: | Pan, Mei-Ren, Hsu, Ming-Chuan, Luo, Chi-Wen, Chen, Li-Tzong, Shan, Yan-Shen, Hung, Wen-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308641/ https://www.ncbi.nlm.nih.gov/pubmed/27531902 http://dx.doi.org/10.18632/oncotarget.11256 |
Ejemplares similares
-
G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation
por: Pan, Mei-Ren, et al.
Publicado: (2015) -
Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer
por: Hsu, Ming-Chuan, et al.
Publicado: (2019) -
Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression
por: Hsu, Ming-Chuan, et al.
Publicado: (2018) -
Functional Role of G9a Histone Methyltransferase in Cancer
por: Casciello, Francesco, et al.
Publicado: (2015) -
Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication
por: Hung, Yu-Hsuan, et al.
Publicado: (2019)